Treating active rheumatoid arthritis with Janus kinase inhibitors

Affiliations

¹ Department of Clinical Rheumatology, King's College London, Weston Education Centre, London SE5 9RJ, UK. Electronic address: d.scott1@nhs.net.
² Department of Health Technology Assessment, Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK.

Free article

Comment

David L Scott et al. Lancet. 2017.

Free article

. 2017 Jul 29;390(10093):431-432.

doi: 10.1016/S0140-6736(17)31659-8. Epub 2017 Jun 16.

¹ Department of Clinical Rheumatology, King's College London, Weston Education Centre, London SE5 9RJ, UK. Electronic address: d.scott1@nhs.net.
² Department of Health Technology Assessment, Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK.

No abstract available

Comment on

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators. Fleischmann R, et al. Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16. Lancet. 2017. PMID: 28629665 Clinical Trial.